A 60day double-blind, placebo-controlled safety study involving Citrus aurantium (bitter orange) extract

Food and Chemical Toxicology

Volumn 55, Issue , 2013, Pages 358-362

  Kaats, Gilbert R ^a   Miller, Howard ^b   Preuss, Harry G ^c   Stohs, Sidney J ^d  

^a Integrative Health Technologies Inc ^*  (United States)

^b Nutratech Inc   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bitter orange; Blood chemistry; Blood pressure; Citrus aurantium; Heart rate; P Synephrine

Indexed keywords

ADVANTRA Z; HESPERIDIN PLUS NARINGIN PLUS PARA SYNEPHRINE; NUTRACEUTICAL; PARA SYNEPHRINE; PLACEBO; SOUR ORANGE EXTRACT; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; HEART RATE VARIABILITY; HUMAN; HUMAN EXPERIMENT; MALE; MONOTHERAPY; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RESTING HEART RATE; SOUR ORANGE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 84873716951     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2013.01.013     Document Type: Article

References (37)

1. Anon, 2010. Dangerous Supplements. What you don't know about these 12 Ingredients could Hurt you. Consumer Reports September, 16-20.
2. Arch J.R. β-3-Adrenoreceptor agonists: potential, pitfalls and progress. Eur. J. Pharmacol. 2002, 440:99-107.
3. Avula B., Upparapalli S.K., Navarrete A., Khan I.A. Simultaneous quantification of adrenergic amines and flavonoids in C. aurantium, various Citrus species, and dietary supplements by liquid chromatography. J. Am. Org. Anal. Chem. Int. 2005, 88:1593-1606.
4. Bent S., Padula A., Neuhaus J. Safety and efficacy of Citrus aurantium for weight loss. Am. J. Cardiol. 2004, 94:1359-1361.
5. Brown C.M., McGrath J.C., Midgley J.M., Muir A.G., O'Brien J.W., Thonoor C.M., Williams C.M., Wilson V.G. Activities of octapamine and synephrine stereoisomers on alpha-adrenoreceptors. Brit. J. Pharmacol. 1988, 93:417-429.
6. Dragull K., Breksa A.P., Cain B. Synephrine content of juice from Satsuma mandarins (Citrus unshiu Marcovitch). J. Agric. Food Chem. 2008, 56:8874-8878.
7. Fugh-Berman A., Myers A. Citrus aurantium, an ingredient of dietary supplements marketed for weight loss: current status of clinical and basic research. Exp. Biol. Med. 2004, 229:698-704.
8. Gougeon R., Harrigan K., Tremblay J.F., Hedrei P., Lamarche M., Morais J.A. Increase in the thermic effect of food in women by adrenergic amines extracted from Citrus aurantium. Obesity Res. 2005, 13:1187-1194.
9. Haaz S., Fontaine K.R., Cutter G., Limdi N., Perumean-Chaney S., Allison D.B. Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update. Obesity Rev. 2006, 7:79-88.
10. Haaz S., Williams K.Y., Fontaine K.R., Allison D.R. Bitter Orange. Encyclopedia of Dietary Supplements 2010, 52-59. Marcel Dekker, New York. second ed. P.M. Coates, M.R. Blackman, G.M. Cragg, M. Levine, J. Moss, J.D. White (Eds.).
11. Haller C.A., Benowitz N.L., Peyton J. Hemodynamic effects of ephedra-free weight loss supplements in humans. Amer. J. Med. 2005, 118:998-1003.
12. Haller C.A., Duan M., Peyton J., Benowitz N. Human pharmacology of a performance-enhancing dietary supplement under resting and exercise conditions. Brit. J. Clin. Pharmacol. 2008, 65:833-840.
13. Hengtmann J.H., Aulepp H. Pharmacokinetics and metabolism of synephrine. Arznei. Forschung 1978, 28:2326-2331.
14. Hwa J., Perez D.M. The unique nature of the serine interactions for alpha 1-adrenergic receptor agonist binding and activation. J. Biol. Chem. 1996, 271:6322-6327.
15. Inchiosa M.A. Evidence (mostly negative) with the use of sympathomimetic agents for weight loss. J. Obesity 2011, 10.1155/2011/764584.
16. Jones, D., 2004. Citrus and Ephedra. Whole Foods. April, pp. 40-41.
17. Jordan R., Thonoor C.M., Williams C.M. Beta-adrenergic activities of octopamine and synephrine stereoisomers on guinea-pig atria and trachea. J. Pharm. Pharmacol. 1987, 39:752-754.
18. Ma G., Bavadekar S.A., Schaneberg B.T., Khan I.A., Feller D.R. Effects of synephrine and beta-phenylephrine on human alpha-adrenoceptor subtypes. Planta Med. 2010, 76:981-986.
19. McGuffin M. Media spins numbers on bitter orange AERs based on erroneous information from FDA. HerbalGram 2006, 69:52-55.
20. Pellati F., Benvenuti S. Chromatographic and electrophoretic methods for the analysis of phenethylamine alkaloids in Citrus aurantium. J. Chromatogr. A 2007, 1171:71-88.
21. Pellati F., Benvenuti S., Melegari M. High-pressure liquid chromatography methods for the analysis of adrenergic amines and flavanones in Citrus aurantium L. var. amara. Phytochem. Anal. 2004, 15:220-225.
22. Penzak S.R., Jann M.W., Cold J.A., Hon Y.Y., Desai H.D., Gurley B.J. Seville (sour) orange juice: synephrine content and cardiovascular effects in normotensive adults. J. Clin. Pharmacol. 2001, 41:1059-1063.
23. Riksen N.P., Smits P., Rongen G.A. The cardiovascular effects of methylxanthines. Handbook Exp. Pharmacol. 2011, 200:413-437.
24. Rossato L.G., Costa V.M., Limberger R.P., de Lourdes Bastos M., Remiao F. Synephrine: from trace concentrations to massive consumption in weight loss. Food Chem. Tox. 2011, 49:8-16.
25. Rozec B., Gauther C. β3-Adrenoreceptors in the cardiovascular system: putative roles in human pathologies. Pharmacol. Therap. 2006, 111:652-673.
26. Sander L.C., Putzbach K., Nelson B.C., Rimmer C.A., Bedner M., Thomas J.B., Porter B.J., Wood L.J., Schrantz M.M., Murphy K.E., Sharpless K.E., Wise S.A., Yen J.H., Siitonen P.H., Evans R.I., Pho A.N., Roman M.C., Betz J.M. Certification of standard reference materials containing bitter orange. Anal. Bioanal. Chem. 2008, 391:2023-2034.
27. Shara M., Stohs S.J. A review of the safety and efficacy of Citrus aurantium in weight management. Obesity: Epidemiology, Pathophysiology and Prevention 2012, 535-554. CRC Press. second ed. D. Bagchi, H.G. Preuss (Eds.).
28. Stohs S.J. A review and assessment of the FDA adverse events reports and clinical case reports between April 2004 and October 2009. J. Funct. Foods 2010, 2:235-238.
29. Stohs S.J., Preuss H.G. The safety of bitter orange (Citrus aurantium) and p-synephrine. HerbalGram 2011, 89:34-39.
30. Stohs S.J., Preuss H.G., Keith S.C., Keith P.L., Miller H., Kaats G.R. Effects of p-synephrine alone and in combination with selected bioflavonoids on resting metabolism, blood pressure, heart rate and self-reported mood changes. Int. J. Med. Sci. 2011, 8:295-301.
31. Stohs S.J., Preuss H.G., Shara M. The safety of Citrus aurantium (bitter orange) and its primary protoalkaloid p-synephrine. Phytother. Res. 2011, 25:1421-1428.
32. Stohs S.J., Preuss H.G., Shara M. A review of the receptor-binding properties of p-synephrine as related to its pharmacological effects. Ox. Med. Cell. Long. doi 2011, 10.1155/2011/482973.
33. Stohs S.J., Preuss H.G., Shara M. A review of the human clinical studies involving Citrus aurantium (bitter orange) extract and its primary protoalkaloid p-synephrine. Int. J. Med. Sci. 2012, 9:527-538.
34. Stohs S.J., Shara M. Safety evaluation of bitter orange extract (p-synephrine) in healthy volunteers. Presented at the annual meeting of the American college of nutrition. Abstract No. 16. J. Am. Coll. Nutr. 2012, 30:358.
35. Talbott, S.M., Christopulos, A.M., Richards, E., 2007. Citrus aurantium Extract has no Effect on Blood Pressure or Heart Rate in Healthy Adults. Unpublished Report. <>. http://www.nutratechinc.com/adz/UploadFile/Talbott%2020907.pdf.
36. Uckoo R.M., Jayaprakasha G.K., Nelson D.S., Patil B.S. Rapid simultaneous determinations of amines and organic acids in citrus using high-performance liquid chromatography. Talanta 2010, 83:948-954.
37. Yang A., Palmer A.A., DeWit H. Genetics of caffeine consumption and responses to coffee. Psychopharmacology 2010, 211:245-257.